1Connelius HG, Nommann SL. Isolation of a low molecular weight inhibitor of lymphocyte proliferation from tumors asites. J Immunol, 1998,141 : 2175.
2Spittler A, Razenberger M, Kupper H, et al. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin Infect Dis,2000,31 : 1338-1420.
3Ye Q,Chen B,Tong Z,et al. Thalidomide reduces IL-18 ,IL-8 and TNF-a release from alveolar macrophages in interstitial lung disease. European Respiratory Journal ,2006,28 : 824-831.
4金惠铭,王建枝主编.病理生理学.第7版.北京:人民出版社,2001.101-103.
5Deng L, Ding W, Granstein RD. Thalidomide inhibits tumor necrosis factor2-ct production and antigen presentation by Langerhans cells. Invest Dermatol,2003 ,121:33-41.
6Michael E, Gordon RM, William DF. Thalidomide. Lancet, 2004,363 : 1802.
7Noman A, Koide N, Hassan F, et al. Thalidomide inhibits lipopolysaccharide -induced tumor necrosis factor-a production via down-regulation of MyD88 expression:Innate Immun,2009,15:33-41.
8Figg WD. Development of thalidomide as an angi ogenesis inhibit or for the treat ment of andr ogen2independent prostate cancer. Clin Phar macol Ther,2006,79 : 1-8.
9Komorowski J, Jerczynska H, Siejka A, et al. Effect of thalidomide affecting VEGF secreti on,cell migrati on, adhesi on and cap illary tube for mati on of human endothelial EA. Hy 926 cells. Life Sci,2005,78:2558 -2563.
10Payvandi F, Wu L. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cellular Immunology, 2004, 230:81-88.
